SMC publishes an updated Collaborative Advice Document for COVID-19 medicines; update for nirmatrelvir plus ritonavir (partial review of TA878)
SMC has published an updated Collaborative Advice Document for COVID-19 medicines, which includes new advice for nirmatrelvir plus ritonavir (Paxlovid) following a partial review. The recommendations are aligned with the updated NICE final guidance for TA878 (13 March 2024).
The updated final guidance includes a Funding Variation for application in NHS England. Scottish Government will issue separate advice regarding implementation in recognition of this aspect for NHS Scotland.
A budget impact template is provided in confidence to NHS boards to enable them to estimate the predicted budget for medicines accepted for use. The updated template reflects the population now covered by the updated advice for nirmatrelvir plus ritonavir (Paxlovid) and incorporates assumptions around the funding variation.
You can find the NICE final guidance here: Overview | Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | Guidance | NICE.
About us
- Who we are
- Horizon scanning
- Public involvement
- Policies & publications
- Minutes
- Meetings
- Register for a meeting
- ILAP
-
Latest update
- HIS website survey
- Speeding up access to new medicines in Scotland: abbreviated process
- International Collaboration
- Joint statement: NICE and SMC/HIS collaboration
- NICE draft recommendations published on the use of treatments for COVID-19
- Healthcare Improvement Scotland
- NICE and SMC/HIS collaboration on health technology appraisal of therapeutics for COVID-19
- Her Majesty Queen Elizabeth II
- April 2022 decisions news release
- New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines
- December 2021 decisions news release
- November 2021 decisions news release
- March 2023 decisions news release
- SMC publishes a Collaborative Advice Document for treatments for COVID-19
- Public Partner Advert
- Fast Track Resubmission Process
- NICE issues final draft guidance for nirmatrelvir plus ritonavir for treating COVID-19 (partial review of TA878)
- SMC publishes an updated Collaborative Advice Document for COVID-19 medicines
- NICE issues final draft guidance on multiple technology appraisal (MTA), ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor– ivacaftor for treating cystic fibrosis.
- SMC publishes Collaborative Advice Documents for ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis.
- Contact us